Vaccine for TB, Stops the Development of MS Symptoms_ New Research
A recent research study revealed that the MS (multiple sclerosis) may be prevented against by a vaccine which is used to treat tuberculosis. The researchers found that t the patients with the symptoms of Ms showed a reducing response in their symptoms and finally these signs were vanished when they were given this vaccine for a certain period. Previously this vaccine is given to the patients with the tuberculosis symptoms like chills, no hunger, fever, weight loss, night sweats, chest pain, fatigue, very bad long time cough or blood with coughing. The vaccine is given to the babies in the areas where TB is a common disease. In modern countries it is used only when a person seems at risk of tuberculosis.
In research the scientist tested the vaccine to stop the symptoms of MS and they found positive results. The research was conducted by a team of specialists in the leadership of Dr. Giovanni Ristori who is employed at Center for Experimental Neurological Therapies in Rome. According to his statement, they discovered this result when they injected the TB vaccine to the persons in which the symptoms of ms were beginning. He demonstrated that study was a good step towards new treatments of ms. He told that they found it a reasonable thing to stop the symptoms of ms to build up. The results of the study were published in the journal Neurology, in his December’s first week editions.
The study was made directly on common human beings as the vaccine was already in use. 73 persons with the symptoms of multiple sclerosis were the subject in study. They were divided into two groups and were kept under observation for 5 years. The first group was injected with the live vaccine and the second group was given placebo injection. The subject persons were gone through MRI after six months. The results showed that the first group injected with the vaccine has weakened ms symptoms three times greater than those injected with placebo.
Then for 1 complete year, these persons were given the medicines commonly used to treat multiple sclerosis. To make the results more precise, these people were permitted to have all kinds of treatments recommended by their doctors. They were permitted to do this for 5 years. Then once again, they were examined for ms symptoms. The results were encouraging. The people injected with vaccines were showing much reduced ms symptoms. The outcomes had showed that the vaccine may stop the multiple sclerosis symptoms to prevail.
The researchers hah following outputs from the study,
1. The vaccine which is used to treat Tuberculosis is also a treatment to stop the symptoms of multiple sclerosis, the ms.
2. The question, how this vaccine works for ms symptoms, is still answerable.
3. Some researchers have a mind that the vaccine stops the swelling of brain nerves.
4. Some of them are thinking that the vaccine is providing some positive boost to immune system to stop ms symptoms.
5. No side effects were observed
The Multiple Sclerosis is disease of nervous system in which some cell structures of brain and spinal cord are damaged and cause poor working and a long range of symptoms such as body imbalance, muscle problems, arms and legs weakness, difficulty in walking, constipation, improper urination and stools, vision problems or complete vision loss, facial pain or ache in the arms and legs, depression, loss of concentration, difficulty in hearing, fatigue, sexual weakness or secretions and a lot more. Once these symptoms appear in the patient, he may get ms disease in 2 to 3 years. It looks clear that such a painful disease really needs a treatment before it may go dominant.
According to Dr. Ristori, the research is still in first phase. They are not going to recommend this vaccine as a full treatment or a preventive medicine. It still needs further experiments. So it is not and may not possibly be marketed on this ground. However the research team is very hopeful and is declaring this research a good measure to the treatment of multiple sclerosis symptoms at the early stages.